Skip to content
Skip to main content

BARCELONA, October 20, 2020 – Splice Bio, a biotech company based on technology developed in the Muir lab at Princeton University, announced today that it has been awared a “RETOS-Colaboración” grant from the Spanish Ministry of Science and Innovation (RTC2019-006879-1).

Related

March 13, 2025

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

December 12, 2024

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

April 10, 2024

SpliceBio to Attend and Present at Key Scientific and Investor Conferences in April to June 2024

Leave a Reply